# Veno-occlusive disease of the liver (sinusoidal obstruction syndrome) after stem cell transplant: prevention, monitoring, diagnosis and defibrotide

Source: https://onco.cc/protocols/hepatic-veno-occlusive-disease-after-transplant/  
OnCo record `hepatic-veno-occlusive-disease-after-transplant` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Veno-occlusive disease is a liver complication of stem cell transplant in which the smallest blood vessels of the liver become blocked, usually in the first three weeks. Teams look for it every day by weighing the patient, examining the abdomen and checking blood tests, because early treatment is linked with better survival. The medicine used is defibrotide, given with careful fluid management.

## Summary

The reader's own unit's policy comes first. Before transplant, assess risk factors and address those that can be changed (BCSH/BSBMT 2013, 1A); ursodeoxycholic acid from conditioning to day +90 is recommended by EBMT for adults (2020) and suggested by BCSH/BSBMT (2C). Heparin, prostaglandin E1, pentoxifylline and antithrombin are not advised for prevention. Monitor weight, abdominal girth, liver size, bilirubin, creatinine and platelet transfusion need daily through the risk period, with baseline imaging in children. Diagnosis: BCSH/BSBMT 2013 uses the modified Seattle or Baltimore criteria (1A); EBMT adult criteria (2016, refined 2023) require bilirubin of 2 mg/dL or more with two of painful hepatomegaly, weight gain over 5% and ascites for clinical disease in the first 21 days, add late-onset disease and a 'probable' category (any two of five signs including imaging); EBMT paediatric criteria (2018) set no time limit and no mandatory bilirubin and count transfusion-refractory thrombocytopenia. Grade severity (EBMT: mild, moderate, severe, very severe). Defibrotide 6.25 mg/kg every 6 hours for at least 21 days is the only licensed treatment (EBMT Handbook): the US label covers disease with renal or pulmonary dysfunction and sets a maximum of 60 days, the European label covers severe disease; EBMT advises starting promptly in severe and very severe disease and early in moderate disease; BCSH/BSBMT recommends it for treatment (1B). The US label contraindicates systemic anticoagulants and fibrinolytics with it, says not to start it during active bleeding, and says to stop the infusion at least 2 hours before an invasive procedure; the European label contraindicates thrombolytics and does not recommend other medicines that raise bleeding risk. Supportive care: cautious fluid and sodium balance, daily creatinine, intake and output, twice-daily weights, enteral rather than parenteral nutrition, and EBMT advises a platelet transfusion threshold of 30 thousand million per litre during defibrotide. Involve critical care and hepatology early (1C). On defibrotide for prevention the sources disagree: a 2023 randomised trial found no benefit and the European Medicines Agency says it is not to be used for prophylaxis, while EBMT's 2026 paediatric consensus supports it in high-risk children. All positions are shown under variants.

## Fields

- Kind: Protocol
- Last checked: 2026-11-17
- Also known as: VOD; SOS; SOS/VOD; hepatic veno-occlusive disease; sinusoidal obstruction syndrome; veno-occlusive disease after transplant; defibrotide treatment; Baltimore criteria; modified Seattle criteria; EBMT VOD criteria; liver complications after bone marrow transplant

## Connected records

- protocols: [GVHD prophylaxis after allogeneic stem cell transplant: choosing the regimen](https://onco.cc/protocols/allo-hct-gvhd-prophylaxis/), [Liver toxicity and veno-occlusive disease on inotuzumab ozogamicin and gemtuzumab ozogamicin: risk reduction, monitoring, hold and stop rules](https://onco.cc/protocols/veno-occlusive-disease-on-inotuzumab-and-gemtuzumab-ozogamicin/), [Raised liver enzymes on targeted anticancer drugs: monitoring, hold and stop rules](https://onco.cc/protocols/raised-liver-enzymes-on-targeted-anticancer-drugs/), [Red cell and platelet transfusion thresholds in cancer care](https://onco.cc/protocols/red-cell-and-platelet-transfusion-thresholds/), [Stem cell transplant: conditioning, the low blood count phase and engraftment monitoring](https://onco.cc/protocols/hct-conditioning-and-engraftment-care/)
- technologies: [Allogeneic stem cell transplantation](https://onco.cc/technologies/allogeneic-hsct/), [Autologous stem cell transplant (high-dose therapy)](https://onco.cc/technologies/autologous-stem-cell-transplant/)
- pairings: [Caution: inotuzumab before transplant (veno-occlusive disease)](https://onco.cc/pairings/inotuzumab-then-transplant-caution/)
- drugs: [Busulfan](https://onco.cc/drugs/busulfan/), [Defibrotide](https://onco.cc/drugs/defibrotide/), [Gemtuzumab ozogamicin](https://onco.cc/drugs/gemtuzumab-ozogamicin/), [Inotuzumab ozogamicin](https://onco.cc/drugs/inotuzumab-ozogamicin/)
- key papers: [Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure](https://onco.cc/key-papers/paper-defibrotide-2005-01-blood-2016/)
- terms: [Conditioning regimen (myeloablative, reduced-intensity)](https://onco.cc/terms/conditioning-regimen/)

---
JSON: https://onco.cc/api/v1/entities/hepatic-veno-occlusive-disease-after-transplant.json